These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 22413789)

  • 1. Demonstrating bioequivalence using clinical endpoint studies.
    Bermingham E; Del Castillo JR; Lainesse C; Pasloske K; Radecki S
    J Vet Pharmacol Ther; 2012 Apr; 35 Suppl 1():31-7. PubMed ID: 22413789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimating product bioequivalence for highly variable veterinary drugs.
    Claxton R; Cook J; Endrenyi L; Lucas A; Martinez MN; Sutton SC
    J Vet Pharmacol Ther; 2012 Apr; 35 Suppl 1():11-6. PubMed ID: 22413787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Challenges associated with the demonstration of bioequivalence of intramammary products in ruminants.
    Lainesse C; Gehring R; Pasloske K; Smith G; Soback S; Wagner S; Whittem T
    J Vet Pharmacol Ther; 2012 Apr; 35 Suppl 1():65-79. PubMed ID: 22413793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Considerations for extrapolating in vivo bioequivalence data across species and routes.
    Modric S; Bermingham E; Heit M; Lainesse C; Thompson C
    J Vet Pharmacol Ther; 2012 Apr; 35 Suppl 1():45-52. PubMed ID: 22413791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing product bioequivalence for extended-release formulations and drugs with long half-lives.
    Gehring R; Martinez M
    J Vet Pharmacol Ther; 2012 Apr; 35 Suppl 1():3-9. PubMed ID: 22413786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishing bioequivalence of veterinary premixes (Type A medicated articles).
    Hunter RP; Lees P; Concordet D; Toutain PL
    J Vet Pharmacol Ther; 2012 Apr; 35 Suppl 1():53-63. PubMed ID: 22413792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Demonstrating comparative in vitro bioequivalence for animal drug products through chemistry and manufacturing controls and physicochemical characterization: a proposal.
    Martinez MN; Fahmy R
    AAPS J; 2015 Mar; 17(2):307-12. PubMed ID: 25609223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Veterinary drug bioequivalence determination.
    Toutain PL; Koritz GD
    J Vet Pharmacol Ther; 1997 Apr; 20(2):79-90. PubMed ID: 9131533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A SAS/IML program for simulating pharmacokinetic data.
    Russek-Cohen E; Martinez MN; Nevius AB
    Comput Methods Programs Biomed; 2005 Apr; 78(1):39-60. PubMed ID: 15780889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current challenges facing the determination of product bioequivalence in veterinary medicine.
    Martinez MN; Hunter RP
    J Vet Pharmacol Ther; 2010 Oct; 33(5):418-33. PubMed ID: 20840385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Computer simulations of bioequivalence trials: selection of design and analyte in BCS drugs with first-pass hepatic metabolism: linear kinetics (I).
    Fernández-Teruel C; Nalda Molina R; González-Alvarez I; Navarro-Fontestad C; García-Arieta A; Casabó VG; Bermejo M
    Eur J Pharm Sci; 2009 Jan; 36(1):137-46. PubMed ID: 19028574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A modified large sample approach in the assessment of population bioequivalence.
    Quiroz J; Ting N; Wei GC; Burdick RK
    J Biopharm Stat; 2000 Nov; 10(4):527-44. PubMed ID: 11104391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioequivalence. An updated reappraisal addressed to applications of interchangeable multi-source pharmaceutical products.
    Marzo A; Balant LP
    Arzneimittelforschung; 1995 Feb; 45(2):109-15. PubMed ID: 7710428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential design approaches for bioequivalence studies with crossover designs.
    Potvin D; DiLiberti CE; Hauck WW; Parr AF; Schuirmann DJ; Smith RA
    Pharm Stat; 2008; 7(4):245-62. PubMed ID: 17710740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blinded sample size re-estimation in crossover bioequivalence trials.
    Golkowski D; Friede T; Kieser M
    Pharm Stat; 2014; 13(3):157-62. PubMed ID: 24715672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variability and impact on design of bioequivalence studies.
    Van Peer A
    Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):146-53. PubMed ID: 20041877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of bioequivalence study regulatory requirements for human and veterinary drugs.
    Grabowski T; Marczak M; Jaroszewski JJ; Whitmire M
    Regul Toxicol Pharmacol; 2012 Nov; 64(2):233-42. PubMed ID: 22917973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Bioequivalence and generic drugs. I. Studies of bioequivalence, considering the theoretical basis, design and use].
    Zapater P; Horga JF
    Rev Neurol; 1999 Dec 16-31; 29(12):1235-46. PubMed ID: 10652753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Model-based analyses of bioequivalence crossover trials using the stochastic approximation expectation maximisation algorithm.
    Dubois A; Lavielle M; Gsteiger S; Pigeolet E; Mentré F
    Stat Med; 2011 Sep; 30(21):2582-600. PubMed ID: 21793036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The subject-by-formulation interaction in multivariate bioequivalence.
    Cao L; Mathew T
    J Biopharm Stat; 2007; 17(3):367-79. PubMed ID: 17479387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.